In summary, the experiences of our previous clinical phase I/II NK cell study for adaptive immunotherapy (Clin-Gov-No-NCT01386619) (6, 41, 42) and our results suggest that highly activated NK cells in combination with TBs, especially ULBP2-aCD19-aCD33, might be an innovative strategy for efficient redirected eliminations of resistant AML cell. Here, ULBP2 is linked to acute myeloid leukemia.